Summit Therapeutics plc
("Summit" or "the Company")
EXERCISE OF WARANTS
Oxford, UK, 14 April 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that it has received notice and payment from N+1 Singer Capital Markets to exercise warrants over 177,045 Ordinary shares of 1.0 pence each at an exercise price of 60.0 pence per Ordinary share.
Summit has applied for admission of the new Ordinary shares to trading on AIM ('Admission'), a market of the London Stock Exchange. It is expected that Admission will become effective on or around 20 April 2016 and the new Ordinary shares will rank pari passu with existing Ordinary shares. Following Admission, the Company will have 61,467,785 Ordinary shares in issue.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 |
-END-